Extracellular matrix proteins and mucins on urogenital epithelial surfaces

The extracellular matrix (ECM) proteins and mucins on urogenital epithelial surfaces form a specialized biochemical barrier essential for maintaining the integrity of the urinary and reproductive tracts (Source: PubMed, PMID: 25635977). This layer includes transmembrane and secreted mucins, such as MUC1 and MUC4, alongside glycosaminoglycans (GAGs) and structural proteins like fibronectin and laminin (Source: NIH, StatPearls). These components function primarily to prevent the adherence of pathogens and protect the underlying epithelium from the caustic effects of urine and other fluids. In clinical contexts, the degradation of this layer is associated with chronic inflammatory conditions like interstitial cystitis, while its protein components are often exploited by bacteria and viruses for initial attachment during infection (Source: Nature Reviews Microbiology). Pharmacological strategies include the use of GAG-replenishment therapies, such as pentosan polysulfate, and anti-adhesion agents that block microbial binding to these surface glycoproteins.

Other names

Urogenital glycocalyxUrothelial mucosal barrierUrogenital extracellular matrixGlycosaminoglycan (GAG) layerUrothelial surface components

Therapeutic agents targeting these surfaces typically function through barrier replenishment, where exogenous glycosaminoglycans restore the protective layer to reduce epithelial permeability, or through competitive inhibition, where molecules like proanthocyanidins prevent bacterial fimbriae from binding to urothelial glycoproteins (Source: PubMed, PMID: 21144344; NIH, StatPearls).